Principal Scientist
ABBVIE
South San Francisco
Catherine obtained her Bachelor's degree from Tsinghua University in Beijing, China, and her Master's degree in Biochemistry from McGill University in Montreal, Canada.
She has been working in the bioanalysis field in the pharmaceuticals industry for more than 20 years, throughout her career, Catherine has worked in several renowned pharmaceutical companies, including Bayer Pharmaceuticals, the legacy of PDL, FACET, Abbott, and Abbvie. Her specialization lies in Ligand Binding Assay (LBA) development, with a focus on PK (pharmacokinetics), Immunogenicity, and Biomarker assay development.
Catherine has made significant contributions to advancing internal pipelines in these companies, taking drug candidates from the discovery stage to the late development stages. Her expertise in biomarker LBA has allowed her to manage the biomarker LBA lab in her current role at ABBVIE Corp. In this position, she oversees the development, qualification, validation, and sample testing of soluble biomarker assays for research, pre-clinical, and clinical studies.
Catherine's work is crucial in addressing important questions about target engagement and the Mechanism of Action (MoA) of drug candidates. By enhancing our understanding of the efficacy, safety, and pharmacological properties of these candidates, Catherine's work contributes to the development of effective and safe pharmaceutical products.
Disclosure information not submitted.
Home-Brew Multiplex Assay on MSD Platform for I-O Drug Development
Monday, October 21, 2024
9:30 AM – 10:00 AM MT